• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

    11/27/24 4:47:13 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Huntsman Ronald Kirk

    (Last) (First) (Middle)
    7921 SOUTHPARK PLAZA,
    SUITE 210

    (Street)
    LITTLETON CO 80120

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vivos Therapeutics, Inc. [ VVOS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/26/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 3,461 D
    Common Stock 69,600 I See footnote(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.64 11/26/2024 A 315,421 (2) 09/07/2034 Common Stock 315,421 $2.64 364,755 D
    Explanation of Responses:
    1. Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
    2. On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027.
    /s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman 11/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VVOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    8/20/25 4:05:35 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Vivos Therapeutics Inc.

    10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)

    8/19/25 4:06:33 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-Q filed by Vivos Therapeutics Inc.

    NT 10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)

    8/14/25 4:15:12 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C

    8/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

    8/13/21 1:08:07 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

    5/18/21 10:44:01 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Skaff Michael C claimed ownership of 1,342,498 shares (SEC Form 3)

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    6/20/25 5:54:04 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:47:13 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:43:54 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Financials

    Live finance-specific insights

    View All

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C

    8/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

    Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invas

    6/11/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vivos Therapeutics Inc.

    SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

    9/24/24 2:59:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care